What is the primary objective of FDA 21 CFR Part 11?

The primary objective of FDA 21 CFR Part 11 is to establish criteria under which the FDA considers electronic records and electronic signatures trustworthy, reliable, and equivalent to paper records and handwritten signatures executed on paper. As stated in §11.1(a), it ensures authenticity, integrity, and, when appropriate, confidentiality of electronic records through controls like validation (§11.10(a)), secure audit trails (§11.10(e)), access limitations (§11.10(d)), and electronic signature requirements (§§11.50–11.300). This equivalency supports inspection readiness (§11.1(e)) while enabling electronic technology use.

Who is legally or professionally required to comply with FDA 21 CFR Part 11?

FDA 21 CFR Part 11 applies to organizations using electronic records created, modified, maintained, archived, retrieved, or transmitted under FDA predicate rules, or submitted electronically to the FDA. Per §11.1(b), it covers life sciences firms (pharma, biotech, devices) relying on electronic records in lieu of paper for regulated activities, or where electronic versions are relied upon despite paper existence (2003 FDA guidance). It excludes paper records transmitted electronically and specific food parts (§11.1(f)–(p)).

Does FDA 21 CFR Part 11 require an external audit or third-party certification?

No, FDA 21 CFR Part 11 does not require external audits or third-party certification. Compliance is demonstrated through internal controls, validation, SOPs, and inspection readiness (§11.1(e)). FDA's 2003 guidance emphasizes self-managed risk-based approaches, with systems and documentation subject to FDA inspection, not mandatory external validation.

How often should an assessment for FDA 21 CFR Part 11 be performed?

FDA 21 CFR Part 11 does not prescribe a fixed frequency for assessments; organizations must perform periodic reviews via change control, risk assessments, and lifecycle management. Per §11.10(k), maintain controls over documentation changes; FDA guidance recommends reassessing scope, validation, and controls during system changes, periodic reviews, or per predicate rules to ensure ongoing fitness for use.

What are the consequences of non-compliance with FDA 21 CFR Part 11?

Non-compliance with FDA 21 CFR Part 11 can result in FDA enforcement actions including Form 483 observations, warning letters, product holds, recalls, and fines under predicate rules. The 2003 guidance notes continued enforcement of access controls (§11.10(d)), checks (§§11.10(f)–(h)), training (§11.10(i)), signatures (§§11.100–11.300)), and predicate violations, as seen in cases like Glenmark involving data integrity failures.

Can FDA 21 CFR Part 11 be mapped to other international frameworks?

FDA 21 CFR Part 11 is not explicitly mapped to other frameworks in its text or 2003 guidance, focusing solely on FDA predicate rules. Organizations may align controls risk-based (e.g., closed/open systems), but compliance stands alone without official cross-references.

What is the first step to begin implementing FDA 21 CFR Part 11?

The first step to implement FDA 21 CFR Part 11 is to establish a formal applicability framework mapping predicate rules to records and assessing business reliance on electronic versions. Per 2003 FDA guidance, document in SOPs whether electronic records replace paper or are relied upon for regulated activities, classifying systems as closed (§11.3(b)(4)) or open (§11.3(b)(9)).

What is the primary objective of BREEAM?

BREEAM's primary objective is to provide a science-led sustainability assessment and certification framework for the built environment. Developed by BRE in 1990, it measures performance across categories like Management, Health & Wellbeing, Energy, Transport, Water, Materials, Waste, Land Use & Ecology, Pollution, and Innovation, converting credits into ratings from Pass (≥30%) to Outstanding (≥85%).

Who is legally or professionally required to comply with BREEAM?

No organizations are legally required to comply with BREEAM, as it is a voluntary certification scheme. Professionally, it applies to developers, owners, and operators of buildings, infrastructure, communities, and fit-outs seeking verified sustainability credentials for market differentiation, ESG reporting, planning incentives, or investor demands.

Does BREEAM require an external audit or third-party certification?

Yes, BREEAM requires third-party certification through licensed BREEAM Assessors and BRE Global quality audits. Assessors compile evidence against scheme manuals and submit for BRE verification under UKAS-accredited ISO/IEC 17065 processes, ensuring impartiality via QA reviews and potential site visits.

How often should an assessment for BREEAM be performed?

BREEAM New Construction assessments occur once per project at design and post-construction stages. For BREEAM In-Use, certifications are valid for 3 years, requiring reassessment for renewal to verify ongoing operational performance.

What are the consequences of non-compliance with BREEAM?

Non-compliance with BREEAM results in no certification and missed benefits like asset value uplift, operational savings, and ESG credibility. As a voluntary scheme, there are no legal penalties, but projects may face planning delays, higher financing costs, or reduced marketability without verified ratings.

Can BREEAM be mapped to other international frameworks?

BREEAM is not explicitly mapped to other frameworks within its core requirements, though Version 7 aligns with EU Taxonomy for technical issues. Its category structure and ratings support comparability for ESG reporting, but scheme-specific manuals and KBCNs govern standalone compliance.

What is the first step to begin implementing BREEAM?

The first step is to select the appropriate scheme (e.g., New Construction, In-Use) and appoint a licensed BREEAM Assessor early at project inception. This enables pre-assessment, credit targeting, and integration into design, procurement, and evidence planning per the technical manual.

Standards Comparison

FDA 21 CFR Part 11 vs BREEAM

FDA 21 CFR Part 11

Mandatory

1997

FDA regulation for trustworthy electronic records and signatures

BREEAM

Voluntary

1990

Global framework for sustainable building certification

Quick Verdict

FDA 21 CFR Part 11 mandates electronic record integrity for life sciences compliance, while BREEAM certifies sustainable buildings voluntarily. Pharma firms adopt Part 11 to avoid FDA penalties; developers use BREEAM for market premiums and ESG credibility.

Electronic Records

FDA 21 CFR Part 11

21 CFR Part 11 Electronic Records; Electronic Signatures

Cost

€€€€

Complexity

Medium

Implementation Time

18-24 months

Key Features

Establishes electronic records/signatures equivalent to paper
Mandates secure, time-stamped audit trails for integrity
Requires unique, non-repudiable electronic signatures
Differentiates controls for closed vs open systems
Enforces risk-based validation and access limitations

Building Sustainability

BREEAM

Building Research Establishment Environmental Assessment Method

Cost

€€€

Complexity

High

Implementation Time

12-18 months

Key Features

Credit-based scoring with category weightings
Third-party certification by BRE Global
10 core sustainability assessment categories
Lifecycle schemes for new-build to in-use
Knowledge Base for continuous compliance updates

Detailed Analysis

A comprehensive look at the specific requirements, scope, and impact of each standard.

FDA 21 CFR Part 11 Details

What It Is

FDA 21 CFR Part 11 is a U.S. regulation establishing criteria for electronic records and electronic signatures to be trustworthy, reliable, and equivalent to paper records and handwritten signatures. It applies to FDA-regulated industries using electronic systems for predicate-rule records. The risk-based approach narrows scope to relied-upon electronic records, with enforcement discretion on some controls.

Key Components

**Subpart AScope, implementation, definitions.
**Subpart BControls for closed (§11.10) and open (§11.30) systems, signature manifestation/linking.
**Subpart CElectronic signature requirements (§§11.100-11.300). Core pillars include validation, audit trails, access controls, training, and non-repudiation. No formal certification; compliance via inspection readiness.

Why Organizations Use It

Ensures data integrity for patient safety and product quality, avoids enforcement actions like warning letters, enables paperless operations, and builds regulator trust. Strategic benefits: efficient inspections, faster decisions.

Implementation Overview

Risk-based CSV lifecycle (GAMP5): scoping, validation (IQ/OQ/PQ), SOPs, training, supplier governance. Applies to life sciences firms; ongoing via change control, audits. (178 words)

BREEAM Details

What It Is

BREEAM (Building Research Establishment Environmental Assessment Method) is a science-led sustainability certification framework for the built environment. Developed by BRE in 1990, it assesses environmental, social, and resilience performance across buildings, infrastructure, and communities. Its credit-based methodology weighs performance in key domains to produce ratings from Pass to Outstanding.

Key Components

**10 core categoriesManagement, Health & Wellbeing, Energy, Transport, Water, Materials, Waste, Land Use & Ecology, Pollution, Innovation.
Hundreds of credits with evidence requirements.
Built on third-party assurance via licensed assessors and BRE audits (ISO/IEC 17065 accredited).
Scheme-specific manuals and living KBCNs for updates.

Why Organizations Use It

Drives ESG compliance, net-zero alignment, and EU Taxonomy support.
Delivers energy savings (22-33%), asset value uplift (up to 30%).
Mitigates regulatory, financial, and reputational risks.
Enhances market differentiation and tenant appeal.

Implementation Overview

Phased: pre-assessment, design integration, construction evidence, certification.
Early assessor/AP appointment essential.
Applies globally to all sizes/types; BRE certification required.

Key Differences

Aspect	FDA 21 CFR Part 11	BREEAM
Scope	Electronic records/signatures trustworthiness	Building sustainability and performance
Industry	Life sciences, pharma, medical devices	Construction, real estate, infrastructure
Nature	Mandatory FDA regulation with discretion	Voluntary third-party certification
Testing	Risk-based system validation, audit trails	Assessor-led credit verification, BRE audits
Penalties	Warning letters, enforcement actions	Loss of certification, no legal penalties

Scope

FDA 21 CFR Part 11

Electronic records/signatures trustworthiness

BREEAM

Building sustainability and performance

Industry

FDA 21 CFR Part 11

Life sciences, pharma, medical devices

BREEAM

Construction, real estate, infrastructure

Nature

FDA 21 CFR Part 11

Mandatory FDA regulation with discretion

BREEAM

Voluntary third-party certification

Testing

FDA 21 CFR Part 11

Risk-based system validation, audit trails

BREEAM

Assessor-led credit verification, BRE audits

Penalties

FDA 21 CFR Part 11

Warning letters, enforcement actions

BREEAM

Loss of certification, no legal penalties

Frequently Asked Questions

Common questions about FDA 21 CFR Part 11 and BREEAM

FDA 21 CFR Part 11 FAQ

BREEAM FAQ

You Might also be Interested in These Articles...

CIS Controls v8.1 for Cloud & Kubernetes: A Practical Implementation Playbook (AWS/Azure/GCP + IaC)

Translate CIS Controls v8.1 to cloud-native: Kubernetes patterns for IAM, logging, vuln mgmt, hardening on AWS, Azure, GCP + IaC. Practical playbook for teams.

Top 10 NIST CSF 2.0 Myths Busted: Separating Hype from Reality for Smarter Adoption

Bust 10 NIST CSF 2.0 myths like 'only for critical infrastructure' or 'Govern replaces Identify'. Plain-English breakdowns, evidence, and fixes for flexible ris

Your Guide to Implementing PCI DSS in Your Organization

Step-by-step guide to implementing PCI DSS in your organization. Achieve compliance, protect cardholder data, and reduce risks. Start securing payments today!

Run Maturity Assessments with GRADUM

Transform your compliance journey with our AI-powered assessment platform

Assess your organization's maturity across multiple standards and regulations including ISO 27001, DORA, NIS2, NIST, GDPR, and hundreds more. Get actionable insights and track your progress with collaborative, AI-powered evaluations.

100+ Standards & Regulations

AI-Powered Insights

Collaborative Assessments

Actionable Recommendations

Explore More Comparisons

See how FDA 21 CFR Part 11 and BREEAM compare against other standards

Other FDA 21 CFR Part 11 Comparisons

Other BREEAM Comparisons

What It Is

Key Components

**Subpart AScope, implementation, definitions.

**Subpart BControls for closed (§11.10) and open (§11.30) systems, signature manifestation/linking.

**Subpart CElectronic signature requirements (§§11.100-11.300). Core pillars include validation, audit trails, access controls, training, and non-repudiation. No formal certification; compliance via inspection readiness.

What It Is

Key Components

**10 core categoriesManagement, Health & Wellbeing, Energy, Transport, Water, Materials, Waste, Land Use & Ecology, Pollution, Innovation.

Hundreds of credits with evidence requirements.

Built on third-party assurance via licensed assessors and BRE audits (ISO/IEC 17065 accredited).

Scheme-specific manuals and living KBCNs for updates.

Aspect

FDA 21 CFR Part 11

BREEAM

Scope

Electronic records/signatures trustworthiness

Building sustainability and performance

Industry

Life sciences, pharma, medical devices

Construction, real estate, infrastructure

Nature

Mandatory FDA regulation with discretion

Voluntary third-party certification

Testing

Risk-based system validation, audit trails

Assessor-led credit verification, BRE audits

Penalties

Warning letters, enforcement actions

Loss of certification, no legal penalties